Daniel Hicklin is an accomplished cancer researcher and biopharmaceutical executive with over 28 years of oncology drug development experience. Dr. Hicklin co-founded Potenza in 2014 and is the company’s President and CEO. He has served as a Managing Director at the life sciences venture capital investment firm MPM Capital since 2014 and is also a board member of Tizona Therapeutics and Harpoon Therapeutics. Previously, Dr. Hicklin served as President and Chief Scientific Officer of CoStim Pharmaceuticals, which was acquired by Novartis in 2014. From 2007 to 2013, he held several positions at Merck Research Laboratories and the former Schering-Plough Research Institute, most recently leading Biologics Strategy for Oncology and overseeing immuno-oncology discovery research at Merck Research Laboratories in Boston. Dr. Hicklin began his drug development career at ImClone Systems where he held several positions of increasing responsibility from 1987 – 2007, most recently serving as Vice President of Experimental Therapeutics. Dr. Hicklin’s team at ImClone supported the development and FDA approval of the cancer treatment ERBITUX® (Cetuximab) and built a diversified portfolio of antibody therapeutics including Cyramza® (ramucirumab), Portrazza® (necitumumab), and other cancer therapies that were acquired by Eli Lilly in 2008. Dr. Hicklin has co-authored over 200 peer-reviewed publications and is an inventor on numerous issued and pending patents. Dr. Hicklin received his Master’s and PhD in Microbiology & Immunology from New York Medical College and earned his BS from the University of Iowa.